Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Non-Current Debt came in at $12.1 billion in Q2 2026, down 27.86% YoY from $16.8 billion in Q2 2025, and down 13.72% on a QoQ basis from $14.0 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Non-Current Debt data on file, last reported at $12.1 billion in Q2 2026.
- Quarterly Non-Current Debt fell 27.86% year-over-year to $12.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.1 billion (down 27.86% YoY) and the FY2025 annual result came in at $15.0 billion, down 6.35% from the prior year.
- Non-Current Debt slipped to $12.1 billion in Q2 2026, from $14.0 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $20.8 billion in Q1 2022 to a low of $12.1 billion in Q2 2026.
- A 5-year average of $17.2 billion and a median of $16.8 billion in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2025 — Non-Current Debt advanced 2.23% — and 2026, when it dropped 27.86%.
- Tracing TEVA's Non-Current Debt over 5 years: stood at $19.1 billion in 2022, then slipped by 4.93% to $18.2 billion in 2023, then declined by 11.89% to $16.0 billion in 2024, then decreased by 6.35% to $15.0 billion in 2025, then declined by 19.31% to $12.1 billion in 2026.
- The last three Non-Current Debt figures came in at $12.1 billion (Q2 2026), $14.0 billion (Q1 2026), and $15.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 130.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 1.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.09 Bn |
| Mar 31, 2026 | 14.02 Bn |
| Dec 31, 2025 | 14.99 Bn |
| Sep 30, 2025 | 16.77 Bn |
| Jun 30, 2025 | 16.76 Bn |
| Mar 31, 2025 | 16.23 Bn |
| Dec 31, 2024 | 16.00 Bn |
| Sep 30, 2024 | 16.40 Bn |
| Jun 30, 2024 | 16.55 Bn |
| Mar 31, 2024 | 16.58 Bn |
| Dec 31, 2023 | 18.16 Bn |
| Sep 30, 2023 | 18.50 Bn |
| Jun 30, 2023 | 18.70 Bn |
| Mar 31, 2023 | 19.67 Bn |
| Dec 31, 2022 | 19.10 Bn |
| Sep 30, 2022 | 18.50 Bn |
| Jun 30, 2022 | 20.36 Bn |
| Mar 31, 2022 | 20.84 Bn |
| Dec 31, 2021 | 21.62 Bn |
| Sep 30, 2021 | 21.04 Bn |